Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations

Archives of Neurology

Volumn 62, Issue 11, 2005, Pages 1684-1688

  Bagnato, Francesca ^a   Gupta, Shiva ^a,c   Richert, Nancy D ^a   Stone, Roger D ^a   Ohayon, Joan M ^a   Frank, Joseph A ^b   McFarland, Henry F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE DURATION; DRUG EFFECT; FEMALE; HUMAN; IMAGE QUALITY; KAPLAN MEIER METHOD; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROPROTECTION; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RELAPSE; SAMPLE SIZE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN; CHI-SQUARE DISTRIBUTION; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 25444485419     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.11.noc40499     Document Type: Article

References (15)

1. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611-619.
2. Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol. 1999;46:850-859.
3. Gasperini C, Pozzilli C, Bastianello S, et al. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images. J Neurol Neurosurg Psychiatry. 1999;67:579-584.
4. 1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain. 2001;124:1396-1402.
5. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol. 2001;49:793-796.
6. Bagnato F, Jeffries N, Ohayon J, et al. A 36-month longitudinal study on the evaluation of the effect of interferon beta in the duration of black holes in multiple sclerosis. Mult Scler. 2002;8(suppl 1):S3.
7. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
9. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999;46:197-206.
10. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60:44-51.
11. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126:1782-1789.
12. Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res. 1998;18:1025-1020.
13. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology. 2001;57:2185-2190.
14. Paolillo A, Bastianello S, Frontoni M, et al. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a. J Neurol. 1999;246:443-448.
15. Bagnato F, Jeffries N, Richert ND, et al. Interferon beta therapy does not affect duration in time of Gd-enhancing lesions and black holes in relapsing remitting multiple sclerosis. Neurology. 2003;60(suppl 1):4-92.